Q4 2025 Earnings Call Transcript September 23, 2025 Operator: Greetings. Welcome to the Aytu BioPharma, Inc. report for ...
Initiation of SSRIs was associated with increased fracture risk among middle-aged women, while other antidepressants were not linked to increased risks.
A phase 2 trial suggests that the novel SNRI ammoxetine may effectively treat major depressive disorder while avoiding some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback